BE2016C023I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2016C023I2 BE2016C023I2 BE2016C023C BE2016C023C BE2016C023I2 BE 2016C023 I2 BE2016C023 I2 BE 2016C023I2 BE 2016C023 C BE2016C023 C BE 2016C023C BE 2016C023 C BE2016C023 C BE 2016C023C BE 2016C023 I2 BE2016C023 I2 BE 2016C023I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03027511 | 2003-11-28 | ||
| EP04803302A EP1691833B1 (fr) | 2003-11-28 | 2004-11-26 | Compositions comprenant des polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2016C023I2 true BE2016C023I2 (fr) | 2023-12-18 |
Family
ID=34626385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2016C023C BE2016C023I2 (fr) | 2003-11-28 | 2016-05-10 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10000574B2 (fr) |
| EP (2) | EP2186527A1 (fr) |
| AT (1) | ATE459374T1 (fr) |
| AU (1) | AU2004293182B2 (fr) |
| BE (1) | BE2016C023I2 (fr) |
| CA (1) | CA2544532C (fr) |
| CY (2) | CY1110689T1 (fr) |
| DE (1) | DE602004025840D1 (fr) |
| DK (1) | DK1691833T3 (fr) |
| ES (1) | ES2341252T3 (fr) |
| FR (1) | FR16C1000I2 (fr) |
| HU (1) | HUS1600019I1 (fr) |
| LU (1) | LU93067I2 (fr) |
| NL (1) | NL300807I2 (fr) |
| PL (1) | PL1691833T3 (fr) |
| PT (1) | PT1691833E (fr) |
| SI (1) | SI1691833T1 (fr) |
| WO (1) | WO2005052004A2 (fr) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140331T1 (hr) | 2006-08-14 | 2014-05-09 | Xencor, Inc. | Optimizirana antitijela usmjerena na cd19 |
| EP2066349B1 (fr) | 2006-09-08 | 2012-03-28 | MedImmune, LLC | Anticorps anti-cd19 humanises et leur utilisation dans le traitement des tumeurs, de la transplantation et des maladies auto-immunes |
| US9308257B2 (en) * | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
| US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
| US8658765B2 (en) | 2009-12-31 | 2014-02-25 | Avidbiotics Corp. | Non-natural MIC proteins |
| WO2012055961A1 (fr) | 2010-10-27 | 2012-05-03 | Micromet Gmbh | Moyens et méthodes de traitement du lymphome b diffus à grandes cellules |
| WO2012123755A1 (fr) | 2011-03-17 | 2012-09-20 | The University Of Birmingham | Immunothérapie redirigée |
| AU2012245260B2 (en) | 2011-04-22 | 2016-09-08 | Aptevo Research And Development Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| KR20240017102A (ko) | 2013-12-17 | 2024-02-06 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법 |
| KR20160089532A (ko) | 2013-12-17 | 2016-07-27 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 항-cd20 항체를 사용하여 암을 치료하는 방법 |
| AP2016009586A0 (en) | 2014-05-29 | 2016-11-30 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
| CN107075548B (zh) | 2014-11-05 | 2021-08-10 | 基因泰克公司 | 在细菌中产生双链蛋白质的方法 |
| WO2016073791A1 (fr) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Procédés de production de protéines à deux chaînes dans des bactéries |
| CA2971288A1 (fr) | 2015-02-02 | 2016-08-11 | The University Of Birmingham | Complexes d'epitope de peptide de fragment de ciblage ayant une pluralite d'epitopes de lymphocyte t |
| HK1255200A1 (zh) | 2015-05-29 | 2019-08-09 | F. Hoffmann-La Roche Ag | 癌症中pd-l1启动子甲基化 |
| IL256080B2 (en) | 2015-06-17 | 2025-06-01 | Genentech Inc | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
| UA126278C2 (uk) | 2015-09-21 | 2022-09-14 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептиди, які зв'язують cd3 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| DK3377103T4 (en) | 2015-11-19 | 2025-05-19 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| EP3178848A1 (fr) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Anticorps de type ii contre cd20 pour la reduction de la formation des anticorps contre des médicaments |
| IL313608A (en) | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| EP3400246B1 (fr) | 2016-01-08 | 2020-10-21 | H. Hoffnabb-La Roche Ag | Procédés permettant de traiter des cancers positifs à cea au moyen d'antagonistes de liaison à l'axe de pd-1 et d'anticorps bispécifiques anti-cea/anti-cd3 |
| EP3252078A1 (fr) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Anticorps de type ii contre cd20 et anticorps bispecifique contre cd20/cd3 pour traitement de cancer |
| WO2018027204A1 (fr) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Anticorps multivalents et multiépitopiques ayant une activité agoniste et procédés d'utilisation |
| WO2018029124A1 (fr) | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Méthodes thérapeutiques et de diagnostic du cancer |
| CN117752798A (zh) | 2016-12-19 | 2024-03-26 | 豪夫迈·罗氏有限公司 | 用靶向性4-1bb(cd137)激动剂的组合疗法 |
| EP3559034B1 (fr) | 2016-12-20 | 2020-12-02 | H. Hoffnabb-La Roche Ag | Thérapie de combinaison d'anticorps bispécifiques anti-cd20/anti-cd3 et agonistes 4 - 1bb (cd137) |
| EP3630829A1 (fr) | 2017-06-02 | 2020-04-08 | H. Hoffnabb-La Roche Ag | Anticorps bispécifique anti-cd20 de type ii et anticorps bispécifique anti-cd20/cd3 pour le traitement du cancer |
| MX2020004573A (es) | 2017-11-01 | 2020-09-25 | Hoffmann La Roche | Terapia de combinacion con agonistas de ox40 dirigidos. |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| AU2019236372B2 (en) | 2018-03-13 | 2024-06-20 | F. Hoffmann-La Roche Ag | Therapeutic combination of 4-1 BB agonists with anti-CD20 antibodies |
| EP3802617A4 (fr) * | 2018-06-07 | 2022-04-27 | Cullinan Oncology, Inc. | Protéines de liaison multi-spécifiques et procédés d'utilisation associés |
| AU2019342133B8 (en) | 2018-09-21 | 2025-08-07 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
| CN113260626B (zh) | 2018-11-05 | 2024-09-13 | 豪夫迈·罗氏有限公司 | 在原核宿主细胞中产生双链蛋白质的方法 |
| US20220204620A1 (en) | 2019-04-30 | 2022-06-30 | Amgen Research (Munich) Gmbh | Means and methods for treating burkitt lymphoma or leukemia |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| KR20250156861A (ko) | 2019-05-21 | 2025-11-03 | 노파르티스 아게 | Cd19 결합 분자 및 이의 용도 |
| WO2021119551A1 (fr) | 2019-12-11 | 2021-06-17 | Cullinan Oncology, Inc. | Anticorps anti-cd19 et protéines de liaison multi-spécifiques |
| CA3182445A1 (fr) | 2020-06-11 | 2021-12-16 | Francisco Leon | Procedes et compositions de prevention du diabete de type 1 |
| KR20230025691A (ko) | 2020-06-16 | 2023-02-22 | 제넨테크, 인크. | 삼중 음성 유방암을 치료하기 위한 방법과 조성물 |
| KR102453073B1 (ko) * | 2020-08-14 | 2022-10-11 | 건국대학교 글로컬산학협력단 | 피키아 파스토리스를 이용한 이중특이적 항체의 제조방법 및 이에 따른 이중특이적 항체 |
| MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
| AU2022253902A1 (en) | 2021-04-10 | 2023-11-02 | Genmab A/S | Folr1 binding agents, conjugates thereof and methods of using the same |
| JP7742892B2 (ja) | 2021-04-23 | 2025-09-22 | ジェンマブ エー／エス | 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法 |
| CA3213632A1 (fr) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosage pour un traitement combine avec un anticorps bispecifique anti-cd20/anti-cd3 et un conjugue anticorps-medicament anti-cd79b |
| EP4083061A1 (fr) * | 2021-04-30 | 2022-11-02 | Kilometro Rosso SPA | Protéines de fusion et leur utilisation dans le traitement de la néphropathie membraneuse |
| EP4329800A1 (fr) | 2021-04-30 | 2024-03-06 | F. Hoffmann-La Roche AG | Dosage pour le traitement avec un anticorps bispécifique anti-cd20/anti-cd3 |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| WO2023076876A1 (fr) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation de réponses immunitaires à des vecteurs viraux |
| US20230414750A1 (en) | 2022-03-23 | 2023-12-28 | Hoffmann-La Roche Inc. | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
| CN119013300A (zh) | 2022-04-13 | 2024-11-22 | 豪夫迈·罗氏有限公司 | 抗cd20/抗cd3双特异性抗体的药物组合物和使用方法 |
| WO2024030956A2 (fr) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Agents de liaison se liant spécifiquement à cd39 et leurs méthodes d'utilisation |
| CN120152989A (zh) | 2022-11-03 | 2025-06-13 | 豪夫迈·罗氏有限公司 | 抗cd19/抗cd28双特异性抗体的组合疗法 |
| AU2024275646A1 (en) | 2023-05-24 | 2025-11-13 | Mozart Therapeutics, Inc. | Cd8-specific binding proteins and methods of using the same |
| AU2024311339A1 (en) | 2023-06-21 | 2026-01-08 | F. Hoffmann-La Roche Ag | Combination therapy with fap-targeted lymphotoxin beta receptor agonists |
| AR133955A1 (es) | 2023-09-26 | 2025-11-19 | Profoundbio Us Co | Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
| WO2025149661A1 (fr) | 2024-01-10 | 2025-07-17 | Genmab A/S | Agents de liaison à slitrk6, conjugués de ceux-ci et leurs procédés d'utilisation |
| US20250381289A1 (en) | 2024-02-29 | 2025-12-18 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| WO2025222129A2 (fr) | 2024-04-19 | 2025-10-23 | Mozart Therapeutics, Inc. | Cytokines modifiées et distribution ciblée de cytokines |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| DK0573551T3 (da) | 1991-02-27 | 2003-08-04 | Micromet Ag | Serinrige peptidlinkere |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5656730A (en) * | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| CA2326389C (fr) * | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Polypeptides specifiques a cd19 et cd3 et leurs utilisations |
| US20020142964A1 (en) * | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
| NZ532896A (en) * | 2001-11-08 | 2007-08-31 | Pdl Biopharma Inc | Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab |
-
2004
- 2004-11-26 AT AT04803302T patent/ATE459374T1/de active
- 2004-11-26 SI SI200431360T patent/SI1691833T1/sl unknown
- 2004-11-26 PT PT04803302T patent/PT1691833E/pt unknown
- 2004-11-26 US US10/580,660 patent/US10000574B2/en active Active
- 2004-11-26 EP EP10155222A patent/EP2186527A1/fr not_active Withdrawn
- 2004-11-26 PL PL04803302T patent/PL1691833T3/pl unknown
- 2004-11-26 DE DE602004025840T patent/DE602004025840D1/de not_active Expired - Lifetime
- 2004-11-26 DK DK04803302.1T patent/DK1691833T3/da active
- 2004-11-26 CA CA2544532A patent/CA2544532C/fr not_active Expired - Lifetime
- 2004-11-26 EP EP04803302A patent/EP1691833B1/fr not_active Expired - Lifetime
- 2004-11-26 ES ES04803302T patent/ES2341252T3/es not_active Expired - Lifetime
- 2004-11-26 WO PCT/EP2004/013445 patent/WO2005052004A2/fr not_active Ceased
- 2004-11-26 AU AU2004293182A patent/AU2004293182B2/en not_active Expired
-
2010
- 2010-05-27 CY CY20101100465T patent/CY1110689T1/el unknown
-
2016
- 2016-05-03 NL NL300807C patent/NL300807I2/nl unknown
- 2016-05-05 HU HUS1600019C patent/HUS1600019I1/hu unknown
- 2016-05-05 CY CY2016010C patent/CY2016010I1/el unknown
- 2016-05-10 BE BE2016C023C patent/BE2016C023I2/fr unknown
- 2016-05-11 LU LU93067C patent/LU93067I2/fr unknown
- 2016-05-20 FR FR16C1000C patent/FR16C1000I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2186527A1 (fr) | 2010-05-19 |
| ES2341252T3 (es) | 2010-06-17 |
| FR16C1000I1 (fr) | 2016-06-24 |
| AU2004293182B2 (en) | 2010-02-18 |
| US20070249529A1 (en) | 2007-10-25 |
| DK1691833T3 (da) | 2010-05-03 |
| PT1691833E (pt) | 2010-06-08 |
| US10000574B2 (en) | 2018-06-19 |
| PL1691833T3 (pl) | 2010-08-31 |
| HUS1600019I1 (hu) | 2016-06-28 |
| WO2005052004A2 (fr) | 2005-06-09 |
| SI1691833T1 (sl) | 2010-06-30 |
| LU93067I2 (fr) | 2016-07-11 |
| DE602004025840D1 (de) | 2010-04-15 |
| CY2016010I2 (el) | 2016-08-31 |
| EP1691833B1 (fr) | 2010-03-03 |
| AU2004293182A1 (en) | 2005-06-09 |
| FR16C1000I2 (fr) | 2017-02-03 |
| CY2016010I1 (el) | 2016-08-31 |
| CA2544532C (fr) | 2015-06-16 |
| CA2544532A1 (fr) | 2005-06-09 |
| WO2005052004A3 (fr) | 2006-03-09 |
| ATE459374T1 (de) | 2010-03-15 |
| NL300807I2 (fr) | 2016-10-13 |
| EP1691833A2 (fr) | 2006-08-23 |
| CY1110689T1 (el) | 2015-06-10 |